Inhalation Sciences
Fredrik Sjövall, CEO, Inhalation Sciences Sweden.Inhalation Sciences Sweden, a portfolio company of Karolinska Development, has received US patent approval for its flagship technology the PreciseInhale system.
The PreciseInhale system is a combination of a highly efficient aerosol generator and a precision dosing aerosol exposure unit. The recently issued US patent protects methods of transporting an aerosol from an aerosol generator to a target lung by an operation including a specially designed aerosol holding chamber. Patent expiry is 2028.
With several key patents protecting the Inhalation Sciences technology around PreciseInhale, three patents issued in the US and three more pending, the recent approval for the core delivery technology at the heart of Inhalation Sciences’s next generation PreciseInhale system is a powerful confirmation of the maturity and gold standard of the platform.
“This patent approval confirms that our approach to generating and dosing aerosols is truly innovative and it makes us even more comfortable with speeding up the ongoing partnering activities,” said CEO Fredrik Sjövall.
Inhalation Sciences Sweden AB, +46 8 5088 45 80, contact@inhalation.se, www.inhalation.se.